BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN BEGIN:VEVENT UID:126@biocityturku.fi DTSTART;TZID=Europe/Helsinki:20230509T140000 DTEND;TZID=Europe/Helsinki:20230509T150000 DTSTAMP:20231013T060327Z URL:https://biocityturku.fi/events/immunology-seminar-tba-2/ SUMMARY:Immunology Seminar: Todd DESCRIPTION:May 9th at 14:00\nVirtual event\n\nJohn Todd\, University of Ox ford\nFrom genetics to disease mechanisms to clinical trials in type 1 dia betes\n\nHost: Riitta Lahesmaa (rilahes@utu.fi )\n\nRegistration latest M ay 8th  at  https://link.webropolsurveys.com/S/9FE7447C1A28E71F\n\nImmu nology seminar series is jointly organised by the Finnish Society for Immu nology\, InFLAMES Flagship and Turku Bioscience. For further information c ontact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi )\, University of Turku.\n\n \;\n\nJohn Todd FRS\, FMedSci\, FRCP Hons \, PhD is Professor of Precision Medicine at the University of Oxford\, Di rector of the Wellcome Centre for Human Genetics and of the JDRF/Wellcome Diabetes and Inflammation Laboratory (DIL)\, and an Emeritus Senior Invest igator of the National Institute for Health Research. Previously\, Todd wa s Professor of Human Genetics and a Wellcome Trust Principal Research Fell ow at the University of Oxford\, and until 2016\, Professor of Medical Gen etics at the University of Cambridge. His PhD was in Biochemistry at the U niversity of Cambridge\, followed by a postdoctoral fellowship at Stanford University.  Todd researches type 1 diabetes (T1D) genetics and disease mechanisms with the goal of delivering clinical interventions. Todd helped pioneer genome-wide genetic studies in common diseases. He then went on t o study the associations between disease-associated genetic variants and p henotypes in T1D by founding and deploying the Cambridge BioResource. In t he latest phase of his research\, to translate basic genetic and immunolog ical knowledge to treatment and prevention\, the DIL is testing the effica cy of low doses of interleukin-2 in newly-diagnosed children with T1D to p reserve the remaining pancreatic islet beta-cell insulin production and in vestigating the role of the microbiome in T1D.\n\n \;\n\nSelected publ ications\n\nJia-Yuan Zhang\, …\, John A. Todd\, Ricardo C. Ferreira. Low -dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammato ry gene expression signature inversely modulated in COVID-19 patients. med Rxiv\, 2023. doi: https://doi.org/10.1101/2022.04.05.22273167\n\nArcadio R ubio García\, Athina Paterou\, …\, Nicola Ternette\, Maki Nakayama\, Jo hn A. Todd\, Marcin L. Pekalski. HLA-DQβ57\, anti-insulin T cells and ins ulin mimicry in autoimmune diabetes. medRxiv\, 2023. doi: https://doi.org/ 10.1101/2022.05.11.22274678\n\nZhang JY\, Hamey F\, Trzupek D\, …\, Todd JA\, Ferreira RC. Low-dose IL-2 reduces IL-21+ T cell frequency and induc es anti-inflammatory gene expression in type 1 diabetes. Nat Commun. 13(1) :7324\, 2022. doi: 10.1038/s41467-022-34162-3\n\nRichardson TG\, Crouch DJ M\, …\, Todd JA\, Davey Smith G. Childhood body size directly increases type 1 diabetes risk based on a lifecourse Mendelian randomization approac h. Nat Commun. 13(1):2337\, 2022. doi: 10.1038/s41467-022-29932-y\n\nWarnc ke K\, Weiss A\, Achenbach P\, von dem Berge T\, …\, Szypowska A\, Todd JA\, Bonifacio E\, Ziegler AG\; GPPAD and POInT Study Groups. Elevations i n blood glucose before and after the appearance of islet autoantibodies in children. J Clin Invest. 132(20):e162123\, 2022. doi: 10.1172/JCI162123 CATEGORIES:BiocityTurku events,Other events END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:DAYLIGHT DTSTART:20230326T040000 TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR